RxDoctor Payments Data

Katherine Robertson

Gerontology · Texarkana, ARNPI 1407203425

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 203 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Among gerontology clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,844in general payments, 2019–2025

Across 203 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$528
  • AstraZeneca$437
  • Pfizer$323
  • Merck$303
  • GSK$247
  • Amgen$231
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$3,833100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,844 in reported general payments places this provider in the 90th percentile of 89 gerontology providers in Arkansas.

See all gerontology providers in Arkansas

Medicare billing

Part B allowed, 2024
$211,753
Medicare patients
318
Services billed
7,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$134,903
OzempicSemaglutide84$107,326
RybelsusSemaglutide47$72,431
FarxigaDapagliflozin Propanediol51$48,048
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog37$42,209
Breztri AerosphereBudesonide/Glycopyr/Formoterol48$32,947
Soliqua 100-33Insulin Glargine/Lixisenatide39$27,777
MounjaroTirzepatide21$23,519
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$23,412
Breo ElliptaFluticasone/Vilanterol27$15,629
Tresiba Flextouch U-100Insulin Degludec27$15,226
JanuviaSitagliptin Phosphate17$6,844
Potassium Chloride236$6,497
Gabapentin259$4,824
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$528$179,757131 claims
PfizerEliquis, Premarin, Paxlovid$323$138,544149 claims
AstraZenecaFarxiga, Breztri Aerosphere$437$80,99699 claims
GSKTrelegy Ellipta, Breo Ellipta$247$39,04061 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$170$27,77739 claims
Lilly USA, LLCMounjaro$207$23,51921 claims
MerckJanuvia$303$6,84417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 89 gerontology providers in Arkansas.

Other gerontology in Texarkana

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →